DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,372 filers reported holding DANAHER CORPORATION in Q1 2019. The put-call ratio across all filers is 1.02 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,590,587 | +9.1% | 9,414 | +0.4% | 0.10% | -1.0% |
Q1 2024 | $2,373,541 | +3.9% | 9,378 | -6.2% | 0.10% | -4.7% |
Q4 2023 | $2,284,632 | +23.2% | 9,994 | +10.0% | 0.11% | +6.0% |
Q3 2023 | $1,854,216 | -23.4% | 9,087 | -3.2% | 0.10% | -20.6% |
Q2 2023 | $2,421,765 | -4.4% | 9,391 | -5.8% | 0.13% | -14.9% |
Q1 2023 | $2,534,480 | +12.8% | 9,965 | +18.0% | 0.15% | +7.2% |
Q4 2022 | $2,246,593 | +9.0% | 8,446 | +2.0% | 0.14% | -6.1% |
Q3 2022 | $2,062,000 | -15.1% | 8,280 | -0.7% | 0.15% | -16.5% |
Q2 2022 | $2,430,000 | +20.0% | 8,336 | +0.3% | 0.18% | +13.5% |
Q1 2022 | $2,025,000 | -6.2% | 8,312 | +4.5% | 0.16% | +1.3% |
Q4 2021 | $2,159,000 | -4.4% | 7,953 | +7.2% | 0.15% | -3.2% |
Q3 2021 | $2,259,000 | -46.9% | 7,418 | -49.4% | 0.16% | 0.0% |
Q2 2021 | $4,258,000 | +130.4% | 14,674 | +104.9% | 0.16% | +3.9% |
Q1 2021 | $1,848,000 | +26.9% | 7,161 | +17.1% | 0.15% | +10.1% |
Q4 2020 | $1,456,000 | +25.2% | 6,117 | +23.5% | 0.14% | 0.0% |
Q3 2020 | $1,163,000 | +34.5% | 4,954 | +13.9% | 0.14% | +27.8% |
Q2 2020 | $865,000 | +49.7% | 4,348 | +17.8% | 0.11% | +21.3% |
Q1 2020 | $578,000 | -3.3% | 3,691 | -0.3% | 0.09% | +20.3% |
Q4 2019 | $598,000 | +12.6% | 3,703 | -4.9% | 0.07% | -1.3% |
Q3 2019 | $531,000 | -2.2% | 3,895 | +1.5% | 0.08% | -3.8% |
Q2 2019 | $543,000 | +12.4% | 3,836 | +0.6% | 0.08% | +9.9% |
Q1 2019 | $483,000 | +21.7% | 3,812 | +1.1% | 0.07% | +20.3% |
Q4 2018 | $397,000 | -11.0% | 3,772 | -18.1% | 0.06% | -10.6% |
Q3 2018 | $446,000 | +15.5% | 4,607 | +17.9% | 0.07% | +10.0% |
Q2 2018 | $386,000 | -6.8% | 3,907 | -7.7% | 0.06% | -15.5% |
Q1 2018 | $414,000 | +6.2% | 4,232 | +0.7% | 0.07% | +10.9% |
Q4 2017 | $390,000 | +15.0% | 4,202 | +6.3% | 0.06% | +10.3% |
Q3 2017 | $339,000 | +421.5% | 3,953 | +394.1% | 0.06% | +241.2% |
Q2 2017 | $65,000 | -77.7% | 800 | -76.5% | 0.02% | -79.3% |
Q1 2017 | $291,000 | +9.8% | 3,408 | 0.0% | 0.08% | -15.5% |
Q4 2016 | $265,000 | -0.7% | 3,408 | 0.0% | 0.10% | -8.5% |
Q3 2016 | $267,000 | -22.4% | 3,408 | 0.0% | 0.11% | -36.1% |
Q2 2016 | $344,000 | +6.5% | 3,408 | 0.0% | 0.17% | -0.6% |
Q1 2016 | $323,000 | +1.9% | 3,408 | 0.0% | 0.17% | +10.6% |
Q4 2015 | $317,000 | +5.0% | 3,408 | -3.9% | 0.15% | -10.1% |
Q3 2015 | $302,000 | -0.7% | 3,548 | 0.0% | 0.17% | +21.7% |
Q2 2015 | $304,000 | +3700.0% | 3,548 | +3483.8% | 0.14% | +3350.0% |
Q1 2015 | $8,000 | -11.1% | 99 | -1.0% | 0.00% | 0.0% |
Q4 2014 | $9,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |